List of Biktarvy drug patents
Biktarvy is owned by Gilead Sciences Inc.
Biktarvy contains Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate.
Biktarvy has a total of 12 drug patents out of which 1 drug patent has expired.
Expired drug patents of Biktarvy are:
- US7803788
Biktarvy was authorised for market use on 07 February, 2018.
Biktarvy is available in tablet;oral dosage forms.
Biktarvy can be used as treatment of hiv infection.
Drug patent challenges can be filed against Biktarvy from February, 2022.
The generics of Biktarvy are possible to be released after 08 November, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(2 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US9732092 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
Dec, 2033
(10 years from now) | |
| US9216996 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
Dec, 2033
(10 years from now) | |
| US9708342 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
Jun, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(11 months ago) | |
|
US7390791
(Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(2 years from now) | |
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
| US10385067 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
Jun, 2035
(12 years from now) | |
| US10548846 | GILEAD SCIENCES INC | Therapeutic compositions for treatment of human immunodeficiency virus |
Nov, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 18, 2026 |
| New Chemical Entity Exclusivity (NCE) | Feb 7, 2023 |
| New Patient Population (NPP) | Jun 18, 2022 |
| M | Feb 24, 2024 |
NCE-1 date: February, 2022
Market Authorisation Date: 07 February, 2018
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic